News

May 14, 2019

Health Canada Approves Adcetris-Chemo for Advanced Classical Hodgkin’s Lymphoma

News

Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s ... Read more

May 9, 2019

Sunlight Exposure Reduces Risk of Non-Hodgkin’s Lymphoma, Study Finds

News

People with high exposure to sunlight or ultraviolet radiation are significantly less likely to develop non-Hodgkin’s lymphoma compared to those with low exposure, but vitamin D levels in the ... Read more

May 7, 2019

Recent Immunosuppression, Persistently High HIV Load Predict Lymphoma Risk

News

Recent immunosuppression, which causes a drop in CD4 T-cell levels, and prolonged exposure to high HIV viral load are two independent predictors of non-Hodgkin’s lymphoma among people living with HIV, ... Read more

May 3, 2019

Forty Seven, Genentech Continue to Test Triple Immunotherapy Combo in DLBCL

News

Forty Seven and Genentech are extending their agreement to include a third clinical trial evaluating a combination of the investigational 5F9 plus Rituxan (rituximab) and Tecentriq (atezolizumab) in patients with diffuse large B-cell lymphoma (DLBCL). The decision builds on ... Read more

May 2, 2019

FasT CAR-T Is Faster, More Potent and Affordable Therapy, Gracell Bio Says

News

Gracell Biotechnologies has developed a platform, called FasT CAR-T, that is able to manufacture its CD19-targeting CAR T-cell product in a single day, as opposed to 14 days for ... Read more

April 30, 2019

Chemotherapy Improves Survival of AIDS-related Lymphoma Patients, Study Finds

News

Patients with AIDS-related lymphoma have better survival outcomes when standard chemotherapy is added to their combined antiretroviral therapy (cART), a new study shows. The study, “The clinical features and ... Read more

April 26, 2019

CAR T Cells Can Directly Target Lymphoma in Mice, Study Finds

News

Using an advanced microscopic technique to visualize how CAR T cells work in a mouse model of lymphoma, researchers found that these cells can induce tumor regression by directly ... Read more

April 23, 2019

Epstein-Barr Vaccination Could Cut Risk of B-cell Lymphoma, Study Suggests

News

Chronic B-cell activation — which can happen because of infectious mononucleosis, commonly caused by the Epstein-Barr virus (EBV) — triggers an excessive proliferation of certain B cells, which can evolve into a B-cell ... Read more

April 18, 2019

Velcade Add-on Doesn’t Improve Survival Outcomes in Newly Diagnosed DLBCL, Trial Shows

News

Adding Velcade (bortezomib) to standard chemotherapy is well-tolerated but does not improve the survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL), even after stratifying patients according ... Read more

April 16, 2019

Japan Designates Valemetostat for Accelerated Development to Treat PTCL

News

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted Sakigake Designation to valemetostat, an investigational treatment for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The designation ... Read more

Pin It on Pinterest